Carmat : Le CÅ“ur des Hommes
Les premiers résultats du cœur artificiel de Carmat sur le taux de survie sont probants et devraient permettre l’obtention d’un marquage CE d’ici le S1 2021 pour un lancement en Europe fin 2021 et aux US fin 2024 selon nos estimations (plus conservatrices que le management). Le véritable défi se situe, selon nous, sur la capacité de production de Carmat pour pouvoir répondre à une demande à MT/LT. Notre valorisation par DCF, intégrant une hausse des Capex et du BFR, aboutit à un ...Carmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.